CNSP — CNS PHARMACEUTICALS INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — |
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 13 SEC-registered investment managers reported holding CNSP (CNS PHARMACEUTICALS INC) in their latest 13F filings, with a combined reported value of $1.62M across 305.29K shares. That is +1.8% by share count (+5.14K shares) versus the previous quarter, while reported value moved +12.9%. Ownership is concentrated: the five largest holders account for 92.1% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 1 added to existing stakes, 4 trimmed. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of CNS PHARMACEUTICALS INC (CNSP) include L & S Advisors Inc, Ikarian Capital, LLC, ADAR1 Capital Management, LLC, ranked by reported 13F value among the 49 institutional holders on this page.
CNSP is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 13 | 305.29K | $1.62M | +1.8% |
| Q2 2026 | 11 | 280.43K | $1.34M | +57.8% |
| Q1 2026 | 12 | 145.61K | $348.70K | +11.3% |
| Q4 2025 | 10 | 117.25K | $1.69M | -94.0% |
| Q3 2025 | 7 | 10.57K | $95.09K | -67.4% |
| Q2 2025 | 11 | 512.76K | $421.80K | +33.5% |
| Q1 2025 | 7 | 40.59K | $55.21K | -64.1% |
| Q4 2024 | 15 | 2.47M | $297.32K | +92.0% |
Over the 8 quarters shown, institutional share counts decreased 88% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q4 2025 (-94.0%).
Top Institutional Holders (Q3 2026) — 13 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 135.83K | $719.90K | 0.11% | Hold | |
| 70.00K | $371.00K | 0.02% | Hold | |
| 39.94K | $211.69K | 0.16% | Reduce | |
| 19.70K | $104.38K | 0.00% | New | |
| 15.76K | $83.53K | 0.00% | Add | |
| 13.52K | $71.68K | 0.00% | Hold | |
| 10.23K | $54.20K | 0.00% | Hold | |
| 150 | $795 | 0.00% | Reduce | |
| 130 | $689 | 0.00% | Reduce | |
| 26 | $136 | 0.00% | New | |
| 8 | $42 | 0.00% | Hold | |
| 1 | $5 | 0.00% | Hold | |
| 1 | $5 | 0.00% | Reduce |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 11 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 135.83K | $649.27K | 0.10% | Add | |
| 70.00K | $334.60K | 0.02% | New | |
| 41.57K | $198.72K | 0.13% | Reduce | |
| 13.52K | $64.64K | 0.00% | Hold | |
| 10.23K | $48.88K | 0.00% | New | |
| 6.99K | $33.43K | 0.00% | New | |
| 1.46K | $6.98K | 0.00% | Add | |
| 799 | $3.82K | 0.00% | Reduce | |
| 19 | $91 | 0.00% | New | |
| 8 | $38 | 0.00% | Hold | |
| 1 | $5 | 0.00% | Hold |
Q1 2026 — 12 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 61.00K | $145.79K | 0.09% | Add | |
| 45.83K | $109.99K | 0.01% | Hold | |
| 23.19K | $55.65K | 0.00% | New | |
| 13.52K | $32.32K | 0.00% | Hold | |
| 1.31K | $3.13K | 0.00% | New | |
| 729 | $1.74K | 0.00% | Add | |
| 16 | $36 | 0.00% | Hold | |
| 8 | $19 | 0.00% | Hold | |
| 3 | $8 | 0.00% | Hold | |
| 1 | $2 | 0.00% | New | |
| 1 | $2 | 0.00% | New | |
| 1 | $2 | 0.00% | Hold |
Q4 2025 — 10 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 8.42K | $1.12M | 0.12% | New | |
| 48.83K | $256.34K | 0.20% | New | |
| 45.83K | $240.61K | 0.03% | New | |
| 13.52K | $71.00K | 0.00% | New | |
| 611 | $3.21K | 0.00% | Reduce | |
| 16 | $113 | 0.00% | New | |
| 8 | $42 | 0.00% | Hold | |
| 4 | $21 | 0.00% | Hold | |
| 3 | $16 | 0.00% | Hold | |
| 1 | $5 | 0.00% | Hold |
Q3 2025 — 7 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 10.52K | $94.68K | 0.00% | Reduce | |
| 28 | $252 | 0.00% | New | |
| 8 | $72 | 0.00% | Reduce | |
| 4 | $36 | 0.00% | Reduce | |
| 3 | $27 | 0.00% | Reduce | |
| 2 | $18 | 0.00% | New | |
| 1 | $9 | 0.00% | New |
Q2 2025 — 11 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 406.00K | $334.95K | 0.01% | New | |
| 32.10K | $26.48K | 0.00% | Add | |
| 23.35K | $19.00K | 0.00% | New | |
| 17.87K | $14.74K | 0.00% | New | |
| 15.63K | $12.90K | 0.00% | New | |
| 10.86K | $8.00K | 0.00% | New | |
| 6.74K | $5.56K | 0.00% | Add | |
| 100 | $83 | 0.00% | Hold | |
| 49 | $40 | 0.00% | Add | |
| 40 | $33 | 0.00% | Hold | |
| 13 | $11 | 0.00% | Reduce |
New Positions (Q3 2026)
- Citadel Advisors 19.70K sh · $104.38K
- Fidelity Management & Research (FMR) 26 sh · $136
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC | 135.83K | 135.83K | 45.83K | 45.83K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ADAR1 Capital Management, LLC | 70.00K | 70.00K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stonepine Capital Management, LLC | 39.94K | 41.57K | 61.00K | 48.83K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Citadel Advisors | 19.70K | — | — | — | — | — | — | 321.87K | — | — | 91.03K | — | — | — | 13.20K | — | — | 20.72K | 55.23K | 81.93K |
| VANGUARD CAPITAL MANAGEMENT LLC | 15.76K | 6.99K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BOOTHBAY FUND MANAGEMENT, LLC | 13.52K | 13.52K | 13.52K | 13.52K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| VANGUARD FIDUCIARY TRUST CO | 10.23K | 10.23K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | 150 | 799 | 1.31K | — | — | 6.74K | 5.11K | — | 16.30K | 115 | 6.77K | 3.98K | 4.74K | — | — | — | — | — | — | — |
| UBS Group AG | 130 | 1.46K | 729 | 611 | 10.52K | 32.10K | 23.98K | 64.42K | 181.87K | 2.63K | — | — | 55 | 1.13K | 2.46K | 1.21K | — | — | — | 3.65K |
| Fidelity Management & Research (FMR) | 26 | — | — | — | — | — | — | — | — | 1 | 14 | 212 | — | — | 200 | — | — | — | — | 25 |
| BARRETT & COMPANY, INC. | 8 | 8 | 8 | 8 | 8 | 100 | 100 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BARCLAYS PLC | 1 | 19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| DANSKE BANK A/S | 1 | 1 | 1 | 1 | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| L & S Advisors Inc | — | — | — | 8.42K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ARMISTICE CAPITAL, LLC | — | — | — | — | — | 406.00K | — | — | — | — | 471.00K | 122.00K | — | — | — | — | — | — | — | — |
| Anson Funds Management LP | — | — | — | — | — | — | — | — | — | 141.40K | — | — | — | — | — | — | — | — | — | — |
| Renaissance Technologies | — | — | — | — | — | — | — | — | — | — | — | 11.14K | — | — | 26.80K | — | 56.80K | — | 506.53K | 147.70K |
| Vanguard Group | — | — | — | — | — | — | — | — | — | — | 58.37K | 58.37K | 23.77K | 23.77K | — | — | 453.62K | 427.70K | 427.70K | 609.41K |
| Geode Capital Management | — | — | 23.19K | — | — | 17.87K | — | 387.06K | 203.18K | — | 28.25K | 24.44K | 24.44K | 16.14K | — | — | 129.02K | 129.02K | 129.02K | 107.26K |
| JANE STREET GROUP, LLC | — | — | — | — | — | — | — | 419.74K | 23.16K | — | 27.39K | — | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold CNSP?
As of 2026-Q3, 13 institutional funds reported holding CNSP (CNS PHARMACEUTICALS INC) in SEC 13F filings, with a combined reported value of $1.62M.
How many shares of CNSP do institutions own?
13F filers reported 305.29K shares of CNSP, worth $1.62M in aggregate at the end of 2026-Q3.
Is institutional ownership of CNSP rising or falling?
Share counts moved +1.8% versus the prior quarter — accumulation.
Who are the top institutional holders of CNSP?
The largest 13F holders are L & S Advisors Inc, Ikarian Capital, LLC, ADAR1 Capital Management, LLC, ARMISTICE CAPITAL, LLC, Anson Funds Management LP; the top 25 are ranked at the top of this page.
Who are the major shareholders of CNS PHARMACEUTICALS INC?
The major shareholders of CNS PHARMACEUTICALS INC (CNSP) by reported 13F value are L & S Advisors Inc, Ikarian Capital, LLC, ADAR1 Capital Management, LLC, ARMISTICE CAPITAL, LLC, Anson Funds Management LP, among 49 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.